These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 7867196)

  • 1. Comparison of the bleeding potential of vampire bat salivary plasminogen activator versus tissue plasminogen activator in an experimental rabbit model.
    Montoney M; Gardell SJ; Marder VJ
    Circulation; 1995 Mar; 91(5):1540-4. PubMed ID: 7867196
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vampire bat salivary plasminogen activator evokes minimal bleeding relative to tissue-type plasminogen activator as assessed by a rabbit cuticle bleeding time model.
    Mellott MJ; Ramjit DR; Stabilito II; Hare TR; Senderak ET; Lynch JJ; Gardell SJ
    Thromb Haemost; 1995 Mar; 73(3):478-83. PubMed ID: 7545321
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Limited fibrin specificity of tissue-type plasminogen activator and its potential link to bleeding.
    Weitz JI
    J Vasc Interv Radiol; 1995; 6(6 Pt 2 Suppl):19S-23S. PubMed ID: 8770837
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An animal model of fibrinolytic bleeding based on the rebleed phenomenon: application to a study of vulnerability of hemostatic plugs of different age.
    Marder VJ; Shortell CK; Fitzpatrick PG; Kim C; Oxley D
    Thromb Res; 1992 Jul; 67(1):31-40. PubMed ID: 1440514
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Distinct dose-dependent effects of plasmin and TPA on coagulation and hemorrhage.
    Stewart D; Kong M; Novokhatny V; Jesmok G; Marder VJ
    Blood; 2003 Apr; 101(8):3002-7. PubMed ID: 12446443
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vampire bat salivary plasminogen activator promotes rapid and sustained reperfusion without concomitant systemic plasminogen activation in a canine model of arterial thrombosis.
    Mellott MJ; Stabilito II; Holahan MA; Cuca GC; Wang S; Li P; Barrett JS; Lynch JJ; Gardell SJ
    Arterioscler Thromb; 1992 Feb; 12(2):212-21. PubMed ID: 1371932
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thrombolytic and haemorrhagic effects of bolus doses of tissue-type plasminogen activator and a hybrid plasminogen activator with prolonged plasma half-life (K2tu-PA: CGP 42935).
    Agnelli G; Pascucci C; Nenci GG; Mele A; Bürgi R; Heim J
    Thromb Haemost; 1993 Aug; 70(2):294-300. PubMed ID: 8236138
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effective thrombolysis without marked plasminemia after bolus intravenous administration of vampire bat salivary plasminogen activator in rabbits.
    Gardell SJ; Ramjit DR; Stabilito II; Fujita T; Lynch JJ; Cuca GC; Jain D; Wang SP; Tung JS; Mark GE
    Circulation; 1991 Jul; 84(1):244-53. PubMed ID: 1905593
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparative study of amyloid-beta (1-42) as a cofactor for plasminogen activation by vampire bat plasminogen activator and recombinant human tissue-type plasminogen activator.
    Kruithof EK; Schleuning WD
    Thromb Haemost; 2004 Sep; 92(3):559-67. PubMed ID: 15351852
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vampire bat salivary plasminogen activator promotes robust lysis of plasma clots in a plasma milieu without causing fluid phase plasminogen activation.
    Hare TR; Gardell SJ
    Thromb Haemost; 1992 Aug; 68(2):165-9. PubMed ID: 1412162
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasmin induces local thrombolysis without causing hemorrhage: a comparison with tissue plasminogen activator in the rabbit.
    Marder VJ; Landskroner K; Novokhatny V; Zimmerman TP; Kong M; Kanouse JJ; Jesmok G
    Thromb Haemost; 2001 Sep; 86(3):739-45. PubMed ID: 11583303
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vampire bat salivary plasminogen activator (desmoteplase): a unique fibrinolytic enzyme that does not promote neurodegeneration.
    Liberatore GT; Samson A; Bladin C; Schleuning WD; Medcalf RL
    Stroke; 2003 Feb; 34(2):537-43. PubMed ID: 12574572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New variant of human tissue plasminogen activator (TPA) with enhanced efficacy and lower incidence of bleeding compared with recombinant human TPA.
    Benedict CR; Refino CJ; Keyt BA; Pakala R; Paoni NF; Thomas GR; Bennett WF
    Circulation; 1995 Nov; 92(10):3032-40. PubMed ID: 7586274
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A bleeding model in rabbits demonstrate fresh clot selectivity for a genetically engineered variant of tissue-type plasminogen activator and for streptokinase.
    Wikström K; Mattsson C; Pohl G
    Thromb Res; 1993 May; 70(3):217-24. PubMed ID: 8392227
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vampire bat salivary plasminogen activator (desmoteplase) inhibits tissue-type plasminogen activator-induced potentiation of excitotoxic injury.
    Reddrop C; Moldrich RX; Beart PM; Farso M; Liberatore GT; Howells DW; Petersen KU; Schleuning WD; Medcalf RL
    Stroke; 2005 Jun; 36(6):1241-6. PubMed ID: 15879331
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fibrin-specificity of a plasminogen activator affects the efficiency of fibrinolysis and responsiveness to ultrasound: comparison of nine plasminogen activators in vitro.
    Sakharov DV; Barrertt-Bergshoeff M; Hekkenberg RT; Rijken DC
    Thromb Haemost; 1999 Apr; 81(4):605-12. PubMed ID: 10235448
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative effects of staphylokinase and alteplase in rabbit bleeding time models.
    Vanderschueren S; Collen D
    Thromb Haemost; 1996 May; 75(5):816-9. PubMed ID: 8725729
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant plasminogen activator inhibitor-1 reverses the bleeding tendency associated with the combined administration of tissue-type plasminogen activator and aspirin in rabbits.
    Vaughan DE; Declerck PJ; De Mol M; Collen D
    J Clin Invest; 1989 Aug; 84(2):586-91. PubMed ID: 2503540
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vampire bat salivary plasminogen activator is quiescent in human plasma in the absence of fibrin unlike human tissue plasminogen activator.
    Gardell SJ; Hare TR; Bergum PW; Cuca GC; O'Neill-Palladino L; Zavodny SM
    Blood; 1990 Dec; 76(12):2560-4. PubMed ID: 2124935
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design of a novel chimeric tissue plasminogen activator with favorable Vampire bat plasminogen activator properties.
    Kazemali M; Majidzadeh-A K; Sardari S; Saadatirad AH; Khalaj V; Zarei N; Barkhordari F; Adeli A; Mahboudi F
    Enzyme Microb Technol; 2014 Dec; 67():82-6. PubMed ID: 25442953
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.